CoChat

Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma

Open access
Grob, Sydney, Mirsky, David M., Donson, Andrew M., Dahl, Nathan, Foreman, Nicholas K., Hoffman, Lindsey M., Hankinson, Todd C., Mulcahy Levy, Jean M. · 2019 · Frontiers in Oncology
Cited by 87

The DOI matches its Crossref record.

Abstract

Adamantinomatous craniopharyngioma (ACP) makes up between 6 and 8% of pediatric brain tumors and is the most common pediatric tumor arising in the sellar/suprasellar region of the brain. The 10-year survival for patients diagnosed with craniopharyngioma ranges between 64 and 92%, but complicating factors such as location, common cyst formation, and potential hypothalamic infiltration cause significant morbidity in this population. There are a number of therapeutic options for children with ACP, including surgery, radiation, and cyst directed therapies such as interferon and bleomycin. Research has raised concerns regarding the efficacy and side effects associated with these conventional therapies, as well as with the difficulty in treating recurrent cystic ACP. Evidence from our group and others has shown that the cystic and solid tumor components of craniopharyngioma have high levels of IL-6R and IL-6, providing a potential target for therapy. Tocilizumab, a humanized monoclonal antibody, acts against soluble and membrane bound IL-6R, and has been widely utilized in pediatric patients. Two patients with recurrent cystic ACP were offered systemically administered tocilizumab or a combination of tocilizumab and bevacizumab on a compassionate use basis. Both patients' tumors had a significant response, with decreased cyst burden, supporting the assertion that tocilizumab with or without bevacizumab may be an option for patients suffering from cystic ACP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2019.00791

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 87

Metadata

Authors
Grob, S., Mirsky, D. M., Donson, A. M., Dahl, N., Foreman, N. K., Hoffman, L. M., Hankinson, T. C., & Mulcahy Levy, J. M.
Venue
Frontiers in Oncology
Published
2019-08-21
Volume
9
Pages
791-791
ISSN
2234-943X (ISSN-L)
OpenAlex
W2965634725
Cited by
87
References
0
FWCI
4.65
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma. https://app.cochat.ai/papers/10.3389/fonc.2019.00791
The paper
Grob, S., Mirsky, D. M., Donson, A. M., Dahl, N., Foreman, N. K., Hoffman, L. M., Hankinson, T. C., & Mulcahy Levy, J. M. (2019). Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma. Frontiers in Oncology. https://doi.org/10.3389/fonc.2019.00791

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.